Attached files
| file | filename |
|---|---|
| EX-4.1 - CERTIFICATE OF DESIGNATIONS - Sanara MedTech Inc. | wndm_ex41.htm |
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 30, 2014
Wound Management Technologies, Inc.
(Exact name of registrant as specified in its charter)
| Texas | 0-11808 | 59-2219994 | ||
| (State or other jurisdiction | (Commission File | (IRS Employer | ||
| incorporation) | Number) | Identification No.) |
| 16633 Dallas Parkway, Suite 250, Addison, Texas | 75001 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code 972-218-0935
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 3.03 Material Modification to Rights of Security Holders.
As described in further detail under Item 5.03 below, on May 30, 2014, the Company filed the Certificate of Designations, designating 5,000 shares of the Company’s Series E Convertible Preferred Stock (“Series E Preferred Stock”).
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
On May 30, 2014, the Company filed a Certificate of Designations, Number, Voting Power, Preferences and Rights of Series E Convertible Preferred Stock (the “Certificate of Designations”), under which it designated 5,000 shares of Series E Preferred Stock. Shares of Series E Preferred Stock are not entitled to any preference with respect to dividends or upon liquidation, and will automatically convert (at a ratio of 1,000 shares of Common Stock for every one share of Series E Preferred Stock) into shares of the Company’s common stock, $0.001 par value upon approval of the Company’s stockholders (and filing of) and amendment to the Company’s Certificate of Incorporation increasing the number of authorized shares of Common Stock from 100,000,000 to 250,000,000.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits.
| Exhibit No. | Description | |
|
Certificate of Designations, Number, Voting Power, Preferences And Rights of Series E Convertible Preferred Stock
|
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
WOUND MANAGEMENT TECHNOLOGIES, INC.
|
|||
|
Date: June 5, 2014
|
By:
|
/s/ Darren Stine | |
|
Darren Stine, Chief Financial Officer
|
|||
3